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Abstract
Andes virus (ANDV) is the major cause of hantavirus pulmonary syndrome (HPS) in South
America. Despite a high fatality rate (up to 40%), no vaccines or antiviral therapies are
approved to treat ANDV infection. To understand the role of endocytic pathways in ANDV
infection, we used 3 complementary approaches to identify cellular factors required for
ANDV entry into human lung microvascular endothelial cells. We screened an siRNA library
targeting 140 genes involved in membrane trafficking, and identified 55 genes required for
ANDV infection. These genes control the major endocytic pathways, endosomal transport,
cell signaling, and cytoskeleton rearrangement. We then used infectious ANDV and retrovi-
ral pseudovirions to further characterize the possible involvement of 9 of these genes in the
early steps of ANDV entry. In addition, we used markers of cellular endocytosis along with
chemical inhibitors of known endocytic pathways to show that ANDV uses multiple routes
of entry to infect target cells. These entry mechanisms are mainly clathrin-, dynamin-, and
cholesterol-dependent, but can also occur via a clathrin-independent manner.
Introduction
Andes virus (ANDV) is a major representative of the NewWorld hantaviruses in the Americas.
It causes hantavirus pulmonary syndrome (HPS) with case fatality rates as high as 40% [1, 2].
HPS is characterized by fever, muscle aches, and headaches, rapidly progressing to pulmonary
edema due to microvascular leakage, and to respiratory failure or shock [3]. At present, ANDV
is the only hantavirus shown to be capable of human-to-human transmission [4]. No effective
vaccines or antiviral drugs exist for HPS.
Hantaviruses are divided into OldWorld hantaviruses, such as Hantaan virus (HTNV) and
Puumala virus (PUUV), and NewWorld hantaviruses like ANDV and Sin Nombre virus.Hanta-
viruses belong to the Bunyaviridae family, and have a tri-segmented, negative-sense, single-
stranded RNA genome. The genome consists of S, M, and L segments encoding the nucleocapsid
(N) protein, 2 glycoproteins (Gn and Gc) produced from a single precursor (GPC), and L protein
(also known as RNA-dependent RNA polymerase, RdRp), respectively. Attachment of ANDV to
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its receptor on host cells is mediated by the virus surface glycoproteins Gn and Gc. Virion uptake
by the infected cells is followed by low pH-dependent fusion between the virus and the endoso-
mal membranes, and the release of ribonucleocapsid cores into the cytoplasm [5].
Hantaviruses use integrins to enter host cells, and pathogenic hantaviruses like ANDV
depend on integrin β3 (ITB3) as their receptor [6–8]. Cell susceptibility to hantavirus, however,
depends not only on the expression of ITB3 [9, 10]; other cellular factors, such as decay-accel-
erating factor (DAF1) and the receptor of complement C1q are also important in hantavirus
entry [11–14]. In addition, integrin β2 was recently identified as a receptor for HTNV and as
responsible for hantavirus pathogenesis [15]. The precise roles of each of these factors in hanta-
virus cell entry are currently unclear, however.
After attaching to the cell membrane, viruses commonly use host endocytic pathways, such
as clathrin-mediated endocytosis, caveolin-mediated endocytosis, and macropinocytosis to
reach intracellular compartments. The major endocytic pathways can be distinguished on the
basis of their differential sensitivity to chemical inhibitors [16]. Using such compounds, previ-
ous studies have shown that HTNV entry involves clathrin and dynamin, but not caveolin-
mediated endocytosis [17, 18]. However, ANDV infectionwas shown to be independent of
both clathrin- and caveolin-mediated endocytosis, suggesting that New and OldWorld hanta-
viruses differentially utilize host cytoskeletal components during their life cycles [18]. Recent
reports have shown consistently that both HTNV and ANDV require cholesterol for cell entry,
an indication of raft-dependent access [12, 19, 20].
Vascular endothelial cells are the primary targets of ANDV infection in humans [21], and
infection in these cells leads to loss of capillary integrity [22]. To better simulate natural ANDV
infection, we used primary human lung microvascular endothelial cells (HMVEC-L) to study
ANDV cell entry. Identifying cellular factors required for ANDV entry into its human target
cells is crucial for understanding how this virus functions, and the results would benefit future
development of antiviral treatments for ANDV infection. To identify such factors, we con-
ducted an siRNA screen that specifically targeted human genes required for endocytosis, intra-
cellular vesicular transport, cell signaling, and cytoskeleton rearrangement. In addition, we
used a panel of chemical inhibitors of endocytic pathways to further probe the mechanisms of
ANDV entry.
Materials and Methods
Cell lines, virus, and antibodies
HMVEC-L (Lonza,Walkersville, MD, USA) were grown with EGM-2MVmedium (Lonza) in
cell culture flasks pre-coated with phosphate-buffered saline (PBS) containing 0.2% gelatin
(Sigma-Aldrich, St. Louis, MO, USA). ANDV (strain Chile 9717869) was propagated in Vero-
E6 cells (obtained from ATCC, Manassas, VA, USA) in a biosafety level 3 laboratory. Viral
titers were determined using immunostaining as describedpreviously [23]. Western blot analy-
ses were used to validate siRNA knockdown of targeted genes, and were performed as
described [23]. The antibodies used for western blotting were directed against ANDV Gc
(1:2000 dilution; catalog no. H1808-60, US Biological, Swampscott, MA, USA), AP2M1
(1:1000; ab75995, Abcam, Cambridge,MA, USA), ARF6 (1:200; sc-7971, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), caveolin-1 (CAV1; 1:1000; 610058, BD Biosciences, San Jose,
CA, USA), CDC42 (1:1000; PA1-092, Thermo Fisher Scientific, Rockford, IL, USA), clathrin
heavy chain (CLTC; 1:500; MA1-065, Thermo Fisher Scientific), dynamin-2 (DNM2; 1:2000;
sc-166669, Santa Cruz), ITB3 (1:100; sc-365670, Santa Cruz), NSF (1:2000; ab16681, Abcam),
RAB5C (1:500; SAB4502559, Sigma-Aldrich), TSG101 (1:200; sc-7964, Santa Cruz), and β-
actin (Sigma-Aldrich).
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Screening the siRNA library
The siRNA library used here (ON-TargetPlus, catalog no. G-105500, Dharmacon, Lafayette,
CO, USA) targets human endocytic and membrane trafficking-related genes. A total of 140
genes was targeted using 4 siRNAs pooled for each gene [24]. All transfections were per-
formed in a 96-well plate format. A 0.5% (v/v) stock of transfection reagent (DharmaFECT
1) was prepared in Opti-MEM solution (Life Technologies) and incubated at 23°C for 5 min.
An equal volume (10 μL) of transfection reagent stock was mixed with rehydrated siRNA in
each well for 20 min at 23°C. Subsequently, 2 × 104 HMVEC-L in 80 μL of EGM-2MVwere
added to each well and incubated for 48 h to allow significant gene knockdown by siRNA.
The final concentration of pooled siRNA was 50 nM. Cell viability assays were also per-
formed in a duplicate experiment to monitor for any cell toxicity caused by siRNA
transfection.
For screening purposes, after transfection with siRNA, ANDV was added to HMVEC-L at
an MOI of 0.5. At 48 h post infection, the cells were fixed at -20°C in absolute methanol
(Sigma-Aldrich) for 20 min. The cells were then subjected to a previously described immunola-
beling assay [23]. Briefly, the cells were washed 3 times with PBS containing 0.1% v/v Tween-
20 (PBS-T), blocked with 5% skimmilk in PBS-T, and incubated at 37°C for 30 min. Plates
were then washed with PBS-T, incubated with mouse monoclonal anti-PUUVN protein anti-
body (1:4000) for 30 min at 37°C, and washed as above. Plates were incubated with 1% H2O2
(Sigma-Aldrich) for 15 min at room temperature, and washed as above. Subsequently, goat
anti-mouse IgG1-conjugated HRP (1:25,000; Southern Biotech, Birmingham, AL, USA) was
added at 37°C for 30 min before washing as above. Signal was detectedwith chemiluminescent
peroxidase substrate-3 (Sigma-Aldrich) on a Synergy HTMicroplate Reader (Biotek, Broad-
view, IL, USA) using 0.1 s integration.
In addition to transfection reagent (DharmaFECT 1) alone, negative controls used were a
non-targeting siRNA, RISC-free siRNA, and siRNA targeting the housekeeping genes cyclo-
philin B, lamin A/C, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (all from
Dharmacon). As positive controls, we included siRNA specifically targeting ANDV genome
segments S or L, which suppressed expression of ANDV N protein in HMVEC-L as described
in [23]. The quality and reliability of the screening result was determined by Z factor (Z0),
which describes the available signal window for an assay in terms of the total separation
between negative and positive controls minus the error associated with each type of control
[25]. It is defined as
Z0 ¼ 1   3
sp þ sn
mp   mn
where σp, σn, μp, and μn are the standard deviations (σ) and the averages (μ) of the positive (p)
and negative (n) controls.
ANDV pseudovirion entry assays
An expression vector encoding the human codon-optimizedANDV GPC gene was synthesized
(DNA2.0, Menlo Park, CA, USA), and HIV pseudoparticles bearing ANDV GPC were pre-
pared as describedpreviously [26]. Briefly, 1 × 106 293T-LentiX cells (Clontech, Mountain
View, CA, USA) were co-transfectedwith plasmid DNA encoding the HIV genome containing
the firefly luciferase gene (pNL4-3.Luc.R-E-) and an expression vector encoding the vesicular
stomatitis virus (VSV) G protein or ANDV GPC. The ratio of HIV plasmid to glycoprotein
expression vector was 8:1. Pseudoparticles were harvested from the medium of 293T-LentiX
cells 48 and 72 h post transfection, and supernatants were combined and filtered to remove
Andes Virus Cell Entry
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cellular debris. Pseudoparticle titers were determined on HMVEC-L cells using the LentiX pro-
virus quantitation kit (Clontech). To measure ANDV glycoprotein-dependent entry, pseudo-
particles were added to HMVEC-L cells and allowed to adsorb for 6 h. After this time, the
inoculumwas removed and replaced with phenol red-free EGM-2-MVmedium (Lonza). Two
days after infection, firefly luciferase levels were measured using the luciferase assay system
(Promega, Madison,WI, USA).
Chemical inhibitor studies
HMVEC-L were incubated at 37°C in low-serum (1% FBS) EGM-2MVmedium supplemented
with the following inhibitors: dynasore (ab120192, Abcam), chlorpromazine (CPZ; C8138,
Sigma-Aldrich), Pitstop 2 (ab120687, Abcam), methyl-β-cyclodextrin (MβCD; C4555, Sigma-
Aldrich), 5-(N-ethyl-N-isopropyl) amiloride (EIPA; A3085, Sigma-Aldrich), LY294002
(S1105, Selleckchem), or cytochalasinD (C8273, Sigma-Aldrich). Cytotoxic effects of these
inhibitors on HMVEC-L were determined using the CellTiter-Glo luminescent assay (Pro-
mega) according to the manufacturer’s instructions, and were expressed as cytotoxic concen-
trations for 20% of the cells (CC20). For inhibitor treatment prior to ANDV or pseudovirion
infection (pre-treatment), cells were treated with inhibitor diluted in low-serum (1% FBS)
EGM-2MVmedium or with an equivalent amount of a DMSO vehicle control for 1 h, and
ANDV (MOI = 0.5) or pseudoparticles (MOI = 1) was added to cells in medium containing
fresh inhibitor. After 3 h (ANDV) or 6 h (pseudovirions), the inoculumwas removed and
replaced with fresh medium containing inhibitor. Two days after ANDV infection, the cells
were fixed in methanol, washed, and stained with PUUV anti-N protein primary antibodies,
followed by AlexaFluor 488-conjugated secondary antibodies (Life Technologies, Grand Island,
NY, USA). Cell nuclei were counterstained with DAPI (1 μg/mL, Life Technologies), and the
plates were then imaged on Operetta High Content Screening system (Perkin Elmer, Waltham,
MA, USA) in wide-field fluorescencemode using the 20× longWD objective. Twenty fields
per well were imaged and analyzed. Subsequent image analyses were performed on Harmony
software (Perkin Elmer) based on counting DAPI-stained nuclei as total cell populations fol-
lowed by texture analysis of AlexaFluor 488-stained cytoplasms to determine the number of
virus-infectedcells. In the case of pseudovirion infection, luciferase assays were performed as
described above.
For inhibitor treatment after ANDV infection (post-treatment), virus was added to cells in
media without inhibitor; inhibitor was added 3 h later. All subsequent procedures were per-
formed as described above.
Dextran and transferrin uptake assay
HMVEC-L were incubated in ice-cold, low-serum (1% FBS) EGM-2MVmedium for 30 min
before inoculationwith ANDV (MOI = 30) for 1 h at 4°C. The cells were washed with ice-cold
PBS, and given ice-cold, low-serumEGM-2MVmedia containing 10 kDa dextran (250 μg/mL)
or transferrin (100 μg/mL) conjugated to AlexaFluor 488 (Life Technologies); the cells were
then incubated for 20 min on ice. Cells were transferred to 37°C for 15 or 30 min, and then
washed 3 times with ice-cold 2 mM PBS glycine (pH 2) before fixing cells with 4% paraformal-
dehyde in PBS, permeabilizing in 0.1% Triton X-100 in PBS, and imaging for immunofluores-
cence. Briefly, cells were stained with polyclonal anti-ANDV primary antibodies and
AlexaFluor 633-conjugated secondary antibodies (Life Technologies), and cell nuclei were
counterstained with DAPI (1 μg/mL). The resulting coverslips were examined by confocal
microscopy.
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Results
A human membrane trafficking siRNA library screen identified genes
required for ANDV infection in HMVEC-L
To elucidate the pathways involved in the ANDV infectious cycle and identify the cellular
genes essential for this process, we screened a commercially available library of siRNAs
directed against genes involved in cellular transport. This screen was performed using pri-
mary HMVEC-L, a physiologically relevant cell type for ANDV replication. HMVEC-L
were transfected with siRNAs, and infected with ANDV (MOI = 0.5) 48 h later. Forty-eight
hours post infection, the cells were fixed and ANDV N protein was detected using a cell-
based enzymatic assay [23]. A Z0 factor above 0.5 was consistently calculated, confirming
the quality of the assay. Cell viability assays performed on mock-infected cells demonstrated
that none of the siRNA pools tested reduced cell viability by more than 20% (data not
shown).
Of the 140 siRNAs screened, 55 inhibited ANDV infection in HMVEC-L, as determined by
analysis of variance (ANOVA) with Bonferroni correction (Fig 1 and S1 Table). These genes
are known to regulate several endocytic pathways, vesicular transport, cell signaling, cytoskele-
tal formation, and exocytosis (S2 Table). None of the siRNAs tested increasedANDV replica-
tion. Of the 55 identified genes, 9 were selected for further characterization, based on their
previously described association with entry pathways of various viruses (Table 1).
Reducing expression of endocytic genes affects ANDV protein
expression and virus release
We first used western blotting to assess the efficiencyof knockdownmediated by each of the
transfected siRNA pools.We found that siRNAs differed in knockdown efficiency, ranging
from 57% to 100% (densitometry data not shown, and Fig 2). The effect of knocking down
each cellular gene on ANDV replication was assessed by western blotting for the viral proteins
N and Gc (Fig 3), and by determining the titers of virus released from the transfected and
infected cells (Fig 4).
Several siRNA pools induced a dramatic reduction in ANDV protein expression and titers.
These included siRNAs targeting DNM2 and CLTC, which reduced ANDV protein expression
to undetectable levels (Figs 2A, 2B and 3A). Furthermore, siRNAs targeting CLTC reduced
virus release from infected cells to nearly undetectable levels (Fig 4).
The knockdown of CAV1, a major scaffolding protein involved in caveolin-mediated endo-
cytosis [27], was only partial (Fig 2D), so the role of caveolin in ANDV entry was unclear. Sup-
pressing the small GTPase ARF6 (Fig 2F), which is involved in many aspects of vesicular
trafficking and actin remodeling and is implicated in macropinocytosis [28, 29], did not signifi-
cantly affect virus protein expression and titers (Figs 3C and 4). Similarly, knocking down the
small GTP-binding protein CDC42 (Fig 2E), an upstream actin regulator involved in the for-
mation of filopodia in macropinocytosis [30, 31], minimally reduced ANDV protein expres-
sion and titers (Figs 3B and 4). The apparent differences between the initial library screening
and the results obtained in these experimentsmay reflect differences between the assays used,
as well as variability in the extent of knockdown of the targeted genes.
Interestingly, knocking down AP2M1 (Fig 2C), a component of an accessory complex com-
monly associated with forming clathrin-coated pits on the plasma membrane [32], appeared to
increase Gc and N protein levels in infected cells (Fig 3B). No reduction in N and Gc protein
levels was detected after knocking down TSG101 (Fig 3F), but viral titers were reduced, sug-
gesting that TSG101 does not affect entry or replication, but rather the subsequent assembly
Andes Virus Cell Entry
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Fig 1. Using an siRNA library to identify genes involved in Andes virus infection of primary human lung cells. Andes virus
(ANDV)-infected primary human macrovascular endothelial lung cells (HMVEC-L) after siRNA administration (blue) were compared
with a negative control set and are presented as the percentage of ANDV-infected cells treated with non-targeting siRNA (NT). The
results are shown as averages (± SD) of 4 independent sets of experiments. Negative control set includes non-targeting siRNA, RISC-
free siRNA, and siRNAs targeting GAPDH, cyclophilin B, and lamin A/C. siRNA pools against the ANDV N segment were used to
demonstrate positive knockdown. ANDV infection (shown in red) is significantly decreased after siRNA knockdown (p < 0.05).
doi:10.1371/journal.pone.0164768.g001
Andes Virus Cell Entry
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and release of progeny virions (Fig 4). Overall, our data indicate that ANDV entry and replica-
tion in HMVEC-L is clathrin- and dynamin-dependent.
ANDV pseudovirion entry in HMVEC-L cells
To determine if the identified genes played a role in ANDV entry or in other steps of ANDV
replication, we usedHIV pseudotyped particles bearing the ANDV glycoprotein. We have
shown previously that entry and consequent expression of the luciferase reporter gene from
these particles are ANDV glycoprotein-dependent [33]. HIV pseudovirions bearing the VSV
glycoprotein G were used as a control. HMVEC-L cells were transfected with the specific siR-
NAs described above, and then transduced with pseudovirions bearing ANDV GPC or VSV G;
luciferase levels were measured 2 days after infection (Fig 5).
As expected, knocking down ITB3 (Fig 5 inset), a known receptor for pathogenic hantavi-
ruses like ANDV [6, 7], inhibited luciferase expression after infectionwith ANDV pseudovir-
ions but not with VSV pseudovirions (Fig 5). This confirms the utility of the pseudovirus
system for studying ANDV glycoprotein-dependent entry. Knocking down DNM2, CLTC, and
AP2M1, factors involved in clathrin-mediated endocytosis, reduced luciferase expression (Fig
5), consistent with a role for this pathway in ANDV glycoprotein-dependent entry. Interest-
ingly, knocking down CDC42 or ARF6 suppressed luciferase expression after infectionwith
ANDV pseudovirions (Fig 5), though not with wild-typeANDV virus (Fig 3).
Chemical inhibition suggests that ANDV uses clathrin-dependent cell
entry in HMVEC-L
Next, we used a panel of chemical inhibitors of endocytosis to probe the endocytic pathways
used by ANDV to enter primaryHMVEC-L (Table 2). First, we tested the cytotoxic effects of
Table 1. Selected genes required for ANDV infection in HMVEC-L.
Gene Gene/Protein Name Function
AP2M1 Adaptor protein complex 2 subunit μ AP-2 is involved in clathrin-dependent endocytosis in which cargo proteins are incorporated into vesicles
surrounded by clathrin (clathrin-coated vesicles) destined for fusion with the early endosome. The AP-2 μ
subunit binds to transmembrane cargo proteins; it recognizes Y-X-X-Phi motifs.
ARF6 ADP-ribosylation factor 6 A GTP-binding protein localized to the plasma membrane, ARF6 is involved in vesicular/protein
trafficking, in regulating endocytic recycling and remodeling of membrane lipids, and in signaling
pathways that lead to actin remodeling.
CAV1 Caveolin-1 Caveolin is the major component of the inner surface of caveolae, small invaginations of the plasma
membrane. It is also a major scaffolding protein in caveolae-mediated endocytosis.
CDC42 Cell division control protein 42
homolog precursor
A plasma membrane-associated small GTPase which cycles between an active GTP-bound and an
inactive GDP-bound state. Along with RAC1 and PAK1, it mediates signaling pathways to activate
macropinocytosis.
CLTC Clathrin heavy chain Clathrin is a major protein component of the cytoplasmic face of intracellular organelles, called coated
vesicles or coated pits. These specialized organelles are involved in intracellular trafficking of receptors
and in endocytosis of a variety of macromolecules. The basic subunit of the clathrin coat is composed of
3 heavy chains and 3 light chains.
DNM2 Dynamin-2 Dynamin is a GTPase involved in producing microtubule bundles for vesicular trafficking processes,
particularly endocytosis.
NSF N-ethylmaleimide-sensitive factor An ATPase required for vesicle-mediated transport, NSF is a component of the SNARE complex. It
functions as a fusion protein required for the delivery of cargo proteins to endosomes and to all
compartments of the Golgi stack independent of vesicle origin.
RAB5C RAS-related protein RAB 5C Members of the RAB protein family are small GTPases of the RAS superfamily, and are thought to
ensure fidelity in docking and/or fusion of vesicles with their correct acceptor compartment.
TSG101 Tumor susceptibility gene 101
protein
A component of the ESCRTI complex, TSG101 binds to ubiquitinated cargo proteins and is required for
sorting endocytic ubiquitinated cargos into multivesicular bodies. It also mediates the association
between the ESCRT0 and ESCRTI complexes.
doi:10.1371/journal.pone.0164768.t001
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each inhibitor in HMVEC-L cells, and subsequently used concentrations of inhibitors that
minimally impacted cell viability (< 20% reduction). In general, these concentrations fell
below those used in a previously published study on continuous cell lines [16].
Each chemical inhibitor was added either 1 h before or 3 h after virus infection, and was pres-
ent during the course of the infection. Among the compounds that were found to inhibit ANDV
infectionwas the dynamin inhibitor dynasore, which is required for the scission step that sepa-
rates the vesicle from the plasma membrane (in clathrin- or caveolin-mediated endocytosis) or
from the intracellular organelle (Table 2). Pitstop 2, which blocks clathrin-mediated endocytosis
(Table 2, [34]), also significantly reduced ANDV infectivity (Fig 6). Pitstop 2 is known to specif-
ically work through blocking protein binding to the N terminus of clathrin, although it can
affect other nonspecific targets in the cell [35]. MβCD, which depletes cellular cholesterol
(Table 2) and inhibits ANDV infection in Vero-E6 cells [19], also blocked ANDV infection of
HMVEC-L. EIPA is a potent and specific inhibitor of the Na+/H+ exchange, and is frequently
used as a specific inhibitor of macropinocytosis [36]. When added prior to infection, EIPA
potently inhibited ANDV infection of HMVEC-L in a concentration-dependent fashion (Fig 6).
In general, adding the compounds after ANDV infection had less effect on infectivity, sug-
gesting that these compounds affect virus entry. Pretreating HMVEC-L cells with CPZ, a
Fig 2. Knockdown of selected genes required for ANDV infection. Western blots of indicated proteins after knockdown with gene-specific
siRNA against (A) dynamin 2 (DNM2); (B) clathrin heavy chain (CLTC); (C) AP2M1; (D) caveolin 1 (CAV1); (E) CDC42; (F) ARF6; (G) NSF;
(H) RAB5C; or (I) TSG101; or non-targeting siRNA transfection control (NT). siRNAs were transfected into HMVEC-L at the concentration of
100 nM for 48 h (see Table 1 for more information regarding these genes). The cells were then infected with ANDV (MOI = 0.5) for 24 h or 48 h.
Western blots were performed post infection to ensure knockdown of the specific protein expression. Molecular weight of each specific protein
is indicated on the right side of each panel. The blots were also probed with β-actin specific antibody as the gel-loading control. (A) and (B)
show only the results collected at 48 h.
doi:10.1371/journal.pone.0164768.g002
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clathrin-mediated endocytosis inhibitor, and with PI3K inhibitor LY294002 did not inhibit
virus entry (S1 Fig). Similarly, pretreating with cytochalasinD, a known inhibitor of actin poly-
merization, had no impact on ANDV infectivity in HMVEC-L (S1 Fig). However, HMVEC-L
cells were extremely sensitive to cytochalasinD treatment, and even very low concentrations
caused extensive cytopathic effect (S2 Fig).
To confirm that the effects of EIPA, dynasore, Pitstop 2, and MβCDwere specific for
ANDV glycoprotein-dependent entry, we tested the ability of these inhibitors to block the
entry of pseudovirions bearing ANDV GPC (Fig 7). Pretreating cells with each compound
caused a concentration-dependent reduction in infection (Fig 7), confirming that these com-
pounds inhibit ANDV entry into HMVEC-L. Interestingly, some of the compounds were more
cytotoxic during these experiments than in ANDV-infected cells.
Fig 3. Effects of knocking down selected genes on ANDV replication. Western blots showing ANDV glycoprotein (Gc) and nucleoprotein
(N) in HMVEC-L transfected with gene-specific siRNAs against (A) DNM2 or CLTC; (B) AP2M1, CAV1, or CDC42; (C) ARF6; (D) NSF; (E)
RAB5C; or (F) TSG101; or with the non-targeting siRNA transfection control (NT). siRNAs were transfected into HMVEC-L at the
concentration of 100 nM for 48 h. Cells were then infected with ANDV (MOI = 0.5) for 24 h or 48 h. Western blots were performed post infection
to examine viral Gc and N protein expression. β-actin was probed as the loading control.
doi:10.1371/journal.pone.0164768.g003
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Fig 4. Knocking down selected host proteins by siRNA decreases ANDV release. Plaque assays to determine titers of ANDV
released by HMVEC-L infected with ANDV after transfection with gene-specific siRNA against DNM2, CLTC, AP2M1, CAV1, CDC42,
ARF6, RAB5C, NSF, or TSG101, or with the non-targeting siRNA transfection control (NT). siRNAs were transfected into HMVEC-L at the
concentration of 100 nM for 48 h, and cells were infected with ANDV (MOI = 0.5) for 48 h. Culture media were harvested, and plaque
assays were performed in Vero-E6 cells. Viral plaques were stained and counted 5 days post-infection and expressed in focus forming unit
(FFU)/mL, as shown on the y-axis of each panel. Results presented are the averages (± SD) of 4 experiments. Statistically significant
differences compared to NT results at the same time points are shown with an asterisk (*; p < 0.05).
doi:10.1371/journal.pone.0164768.g004
Fig 5. siRNA profiling of selected genes required for recombinant ANDV pseudovirion infection. Gene-specific siRNA against integrin β3
(ITB3), DNM2, CLTC, AP2M1, CDC42, or ARF6, or the non-targeting siRNA transfection control (NT), were transfected into HMVEC-L at the
concentration of 100 nM for 48 h. Cells were infected with pseudovirions (MOI = 1) for 48 h. All pseudovirions consisted of an HIV backbone with firefly
luciferase, and were pseudotyped with ANDV GPC (ANDV) or vesicular stomatitis virus G protein (VSV). Effects of gene knockdown were measured
by quantifying luciferase activity in the host genome. Solid bars represent ANDV, and open bars represent VSV. Luciferase activity is expressed as
units relative to non-targeting siRNA control (% infection). The effect of ITB3-specific siRNA knockdown is shown in the inset. Results presented are
the averages (± SD) of 10 experiments (n = 10), and significant decreases in pseudovirion infection (p < 0.05) after siRNA knockdown are shown with
an asterisk (*).
doi:10.1371/journal.pone.0164768.g005
Andes Virus Cell Entry
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Altogether, these data suggest that ANDV uses clathrin- and cholesterol-dependent cell
entry pathways, while inhibition with EIPA also implicates entry via a mechanism similar to
macropinocytosis in HMVEC-L cells.
ANDV partially co-localizes with both transferrin and fluorescent dextran
molecules
To further elucidate any possible role of macropinocytosis in ANDV entry into primary lung
cells, we traced the internalization of ANDV and dextran, a fluorescent fluid phase marker
[37]. HMVEC-Lwere inoculatedwith ANDV (MOI = 30), washed, and incubated with dextran
conjugated to AlexaFluor 488 (Fig 8, top row) or with labeled transferrin (Fig 8, middle row).
Confocalmicroscopy revealed that ANDV virions (shown in red) colocalizedwith dextran
(green, Fig 8, top row). At 30 min post virus entry, large inclusions were observedwhen cells
were co-stained for both virus antigen and dextran.We found that the ratio of those large
inclusions to the punctate staining also observed intracellularly was approximately 1:1. The
size of the larger inclusions was variable, but they were significantly bigger than the punctate
staining.We do not know if the large inclusions are physiologically relevant at this point. The
fact that they are not present at 15 min post entry (second row in the Fig 8) indicates that they
are not virus aggregates created during virus stock preparation, but are areas of intracellular
virus accumulation. These results suggest that ANDV can enter primary cells via multiple
endocytoticmechanisms, including clathrin-dependent endocytosis, and possibly implicate
macropinocytosis in virus entry.
Discussion
In the present study, we identified cellular pathways by which ANDV enters primary
HMVEC-L, a physiologically relevant cell type.We initially used an siRNA library to identify
important genes, and subsequently used chemical inhibitors of endocytosis to probe ANDV
cell entry mechanisms. Our data indicate that ANDV enters primary human lung cells by cla-
thrin-mediated endocytosis, though some evidence for an additional macropinocytosis-like
entrymechanism was also found.
Viruses can use several pathways to enter cells, althoughmany of them will preferentially
use one pathway, depending on the cell type [38–42]. Hantavirus infection is a multi-step pro-
cess initiated by cell surface attachment and followed by internalization of virions, converging
toward the early endosome [5]. A previous study showed that pre-treatment with
Table 2. Chemical inhibitors of endocytic pathways used in this study.
Inhibitor Endocytosis Pathway Blocked Specific Activity Toxicity to HMVEC-L
(CC20)
Dynasore Clathrin and caveolin Blocks dynamins 87 μM
Chlorpromazine(CPZ) Clathrin Prevents coated pit formation by blocking AP2 binding to
receptor
22 μM
Pitstop 2 Clathrin Prevents coated pit formation by blocking attachment to
clathrin heavy chain
16 μM
Methyl-β-cyclodextrin (MβCD) Caveolin, clathrin, and
macropinocytosis
Extracts cholesterol from cells 2 mM
5-(N-ethyl-N-isopropyl) amiloride
(EIPA)
Macropinocytosis Inhibits Na+/H+ exchange 51 μM
LY294002 Macropinocytosis Inhibits PI3K α/β/δ 13 μM
Cytochalasin D Clathrin and macropinocytosis Disrupts actin polymerization 300 nM
doi:10.1371/journal.pone.0164768.t002
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chlorpromazine or filipin did not significantly decrease ANDV infection, and concluded that
ANDV does not use either clathrin- or caveolin-mediated endocytosis to enter Vero-E6 cells
[18]. Another study showed that ANDV entry is inhibited by the cholesterol inhibitor mevasta-
tin in Vero-E6 cells, suggesting that entry may occur through endocytosis via lipid rafts [19]. In
addition to these seemingly contradictory findings, ITB3, a receptor for pathogenic
Fig 6. Productive ANDV infection in HMVEC-L depends on dynamin, cholesterol, and clathrin pathways.
HUMVEC-L viability (red lines) and level of ANDV infection (blue bars) when using varying concentrations of the
indicated inhibitors. For inhibitor pretreatment (Pre), HMVEC-L were treated with dynasore, MβCD, Pitstop 2, or
EIPA for 1 h before inoculating with ANDV (MOI = 1) in the presence of the inhibitor. For post-treatment (Post), cells
were infected with ANDV; after 3 h, virus was removed and media replaced with low-serum medium containing
inhibitor. Infection was assessed 16 h post infection by immunofluorescence assay. Percentages of infected and
viable cells were determined relative to untreated controls (UC). Results presented are the averages (± SD) of
triplicate experiments. Recombinant VSV virus (rVSV) infection was also used as a control (S3 Fig).
doi:10.1371/journal.pone.0164768.g006
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hantaviruses including ANDV, is internalized by both clathrin- and non-clathrin-dependent
endocytosis [43, 44].
We found that cellular genes like DNM2 and CLTC were essential for ANDV entry into
HMVEC-L, suggesting entry via clathrin-mediated endocytosis. These results were supported
by inhibition of ANDV and pseudovirion infection by the chemical inhibitors dynasore and
Pitstop 2.
CPZ is an antipsychotic agent that has been implicated in clathrin-mediated endocytosis
because it blocks the interaction of AP2 with clathrin during the formation of clathrin-coated
pits. However, CPZ can also bind to other proteins, including calmodulin, channel proteins,
and other membrane proteins, and more recently has been shown to trigger autophagy without
causing cell death [45]. Actually, treatment with CPZ did not inhibit ANDV infection, but
rather enhanced ANDV infection (S1A Fig). A probable explanation for this result is that CPZ
is known to induce cell autophagy, and ANDV utilizes autophagy for efficient replication [33,
46]. CPZ treatment is also known to inhibit virus entry in continuous cell lines, but not in a
number of primary cell lines, particularly in HMVEC-L cells [38].
Unlike clathrin-dependent endocytosis, no single protein coat, cellular factor, chemical
inhibitor, or feature definesmacropinocytosis [16, 31]. Experimental criteria have been
Fig 7. ANDV pseudovirion entry into HMVEC-L utilizes clathrin-mediated endocytosis and is cholesterol-
dependent. Percent HMVEC-L viability (red lines) and ANDV infection (blue bars) after treatment with indicated
inhibitors and infection with pseudovirions expressing luciferase and ANDV glycoprotein (GPC). HMVEC-L were
treated with dynasore, MβCD, Pitstop 2, or EIPA as in Fig 6 before inoculating with ANDV pseudovirions
(MOI = 1) in the presence of inhibitor. After 6 h, virus was removed and replaced with low-serum medium
containing inhibitor. Infection was assayed 40 h later by measuring luciferase activity. Percentages of viable and
infected cells were determined relative to untreated control (UC). Results presented are the averages (± SD) of
triplicate experiments.
doi:10.1371/journal.pone.0164768.g007
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recommended for determiningwhether a virus uses the macropinocytic pathway, with the
caveat that the extent of entry through this pathway can differ with cell type [31]. Na+/H+
exchangers, such as EIPA, are understood to be important indicators of viral entry by macropi-
nocytosis, and we found that EIPA potently inhibited ANDV entry. Moreover, ANDV co-
localizedwith high molecular weight dextran within intracellular vacuoles. Macropinocytosis
can be a direct viral entrymechanism, or be used indirectly, by virions first binding to receptors
in clathrin-coated pits, and then being enclosed by lamellipodia or circular ruffles to complete
Fig 8. Co-localization of ANDV with high molecular weight dextran and transferrin in HMVEC-L. Confocal images of HMVEC-L treated with high
molecular weight dextran or transferrin and infected with ANDV. ANDV is shown in red and was stained with anti-ANDV polyclonal antibodies and
AlexaFluor 633-conjugated secondary antibodies. Green represents 10 kDa dextran or transferrin conjugated to AlexaFluor 488. Host nuclei were
stained blue with DAPI. Confocal images were taken 15 or 30 min post infection, as indicated. White arrows indicate co-localization of ANDV with dextran
or transferrin. Arrowheads show areas of intracellular viral accumulation. Bar, 10 μm.
doi:10.1371/journal.pone.0164768.g008
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the engulfing process [31]. Whether such sequential, coordinated actions between endocytic
pathways act during ANDV entry remains to be elucidated.
Actin is required for clathrin-mediated endocytosis or macropinocytosis [47]. As men-
tioned earlier, treatment with EIPA, which can also induce reorganization of the actin struc-
ture [48], suppressed ANDV entry by these mechanisms. However, the actin polymerization
inhibitor cytochalasinD had no impact on ANDV infectivity in HMVEC-L at the maximum
concentration used (250 nM). The reason for these seemingly contradictory results is that
cytochalasinD caused extensive cytotoxicity to HMVEC-L cells before reaching the concen-
trations of 2–3 μM known to be necessary to disrupt actin polymerization [49]. In addition to
cytochalasinD, pretreating HMVEC-L cells with PI3K inhibitor LY294002 did not inhibit
virus entry, also indicating that ANDV entry is PI3K-independent. These results are shown in
S1 Fig.
Interestingly, knocking downmacropinocytosismarkers PAK-1 (Fig 1), CDC42 (Figs 3 and
4), and ARF6 (Figs 3 and 4) did not significantly reduce ANDV infection.However, another
main marker of macropinocytosis, Rho GTPase RAC1, significantly contributed to ANDV
infection, as shown in Fig 1. It is possible that when Rho GTPases like CDC42 are inhibited,
other GTPases substitute their function. Knocking down genes encodingWASF2 andWASF3,
members of theWiskott-Aldrich syndrome protein family, also affected virus replication (Fig
1). These gene products form a multiprotein complex that links receptor kinases and GTPases
with actin and ultimately facilitates non-clathrin mediated endocytosis.
While validating the involvement of endocytic genes identified in the initial siRNA library
screening, we found that knocking down NSF and TSG101 had little effect on the expression of
ANDV N and Gc proteins, but significantly reduced virus release, suggesting that these pro-
teins are involved in viral assembly or budding, but not in entry or replication. These proteins,
or their associated proteins, are thus potential cellular targets for anti-ANDV therapies.
In conclusion, our results suggest that ANDV can use clathrin-mediated endocytosis to
enter a physiologically relevant host cell type. ANDV entry is also dynamin- and cholesterol-
dependent. Additionally, a clathrin-independent pathway is involved; this pathway shares
some features with macropinocytosis, but the exact mechanism remains to be determined.
These pathways should be considered when designing antiviral therapies targeting the entry
mechanism.
Supporting Information
S1 Fig. Effects of chlorpromazine, cytochalasinD, and LY294002 on ANDV infection in
HMVEC-L.Viability curve (red line) and percentage of ANDV-infected HMVEC-L (blue
bars) after treatment with indicated concentrations of (A) chlorpromazine, (B) cytochalasinD,
or (C) LY294002. Cells were incubated with inhibitor for 1 h prior to ANDV infection
(MOI = 1). After 3 h, virus was removed and replaced with low-serummedium containing
inhibitor. ANDV presence was determined 16 h after infection by immunostaining the N pro-
tein. Viability and percentages of infected cells were calculated relative to untreated controls
(UC). Results presented are the averages (± SD) of triplicate experiments.
(TIF)
S2 Fig. Cytotoxicity of cytochalasinD in HMVEC-L.Viability curve of HMVEC-L after treat-
ment with indicated concentrations of cytochalasinD. Cells were incubated with inhibitor for
16 h before viability was determined relative to untreated controls (UC). Results presented are
the averages (± SD) of triplicate experiments.
(TIF)
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S3 Fig. Effects of Pitstop 2, EIPA, MβCD, dynasore, and chlorpromazineon recombinant
VSV infection in HMVEC-L.Viability curve (red line) and percentage of rVSV-infected
HMVEC-L (blue bars) after treatment with indicated concentrations of (A) Pitstop 2, (B)
EIPA, (C) MβCD, (D) dynasore, or (E) chlorpromazine. Cells were incubated with inhibitor
for 1 h prior to rVSV infection (MOI = 1). After 3 h, virus was removed and replaced with low-
serummedium containing inhibitor. rVSV presence was determined 8 h after infection by the
fluorescent intensity of GFP expressed from rVSV. rVSV was produced from Vero-E6 cells
transfected with KeraFAST VSV-ΔG-GFP plasmid expression vectors and pseudotypedwith
VSV G. Viability and percentages of infected cells were calculated relative to untreated controls
(UC). Results presented are the averages (± SD) of triplicate experiments.
(TIF)
S1 Table. Results of siRNA screening.
(DOCX)
S2 Table. Genes identified by siRNA library screening that affect ANDV infection of
HMVEC-L.
(DOC)
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